These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19758686)

  • 21. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future perspectives in systemic therapy. Conclusion of the expert meeting of the University of Würzburg.
    Burk K; Wirth M; Frohmüller H
    Prog Clin Biol Res; 1989; 303():549-58. PubMed ID: 2675012
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.
    Sabel MS; Arora A; Su G; Chang AE
    Cryobiology; 2006 Dec; 53(3):360-6. PubMed ID: 16973145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of imaging in the surveillance of urologic malignancies.
    Bradford TJ; Montie JE; Hafez KS
    Urol Clin North Am; 2006 Aug; 33(3):377-96. PubMed ID: 16829272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What are the contributions of experimental studies to the diagnosis and therapy of urological tumors?].
    Debruyne FM; Oosterhof GO; Schalken JA
    Verh K Acad Geneeskd Belg; 1991; 53(1):29-37; discussion 38. PubMed ID: 2053419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal therapy for urologic cancers.
    Bochner BH; Scardino PT
    Nat Clin Pract Urol; 2006 Sep; 3(9):453. PubMed ID: 16964179
    [No Abstract]   [Full Text] [Related]  

  • 33. Exercise and urologic cancers.
    Drouin JS; Beeler J
    Urol Oncol; 2008; 26(2):205-12. PubMed ID: 18312944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer immunotherapy: new applications in urologic oncology.
    Mullane SA; Bellmunt J
    Curr Opin Urol; 2016 Nov; 26(6):556-63. PubMed ID: 27584023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine gene transfer for the treatment of cancer.
    Bruyns C; Gérard C; Velu T
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S17-20. PubMed ID: 8177710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with radiotherapy in urological malignancies.
    Mehta S; Illidge T; Choudhury A
    Curr Opin Urol; 2016 Nov; 26(6):514-22. PubMed ID: 27552139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.
    Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA
    Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [AUO guidelines. Practical information for planning and execution of studies 1993. Association of Urologic Oncology].
    Urologe A; 1993 Mar; Suppl 1():S1-35. PubMed ID: 8493755
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.